The major targets for PD drug development for management include the LRRK2, neurotrophic factors, alpha-synuclein, cell therapy, antioxidants, the microbiome, and GIT and dopamine precursors that will be the futuristic approaches to overcome PD [94]. Here, SNCA is linked to Parkinson disease.